Your browser doesn't support javascript.
loading
Biomarker context-of-use: how organizational design can impact the implementation of the appropriate biomarker assay strategy.
J Cowan, Kyra; Golob, Michaela; Goodman, Joanne; Laurén, Anna; Andersen, Lene; Decker, Philip De; Dejager, Lien; Fjording, Marianne Scheel; Groenen, Peter; Jasnowski, Renaud; Justies, Nicole; Kimberg, Matti; Kunz, Ulrich; Lawrence, James; Richter, Mario; Sordé, Laetitia; Trigt, Radboud van; Vermet, Laurent; Vitaliti, Alessandra; Wright, Michael; Timmerman, Philip.
Afiliación
  • J Cowan K; Merck KGaA, New Biological Entities Drug Metabolism & Pharmacokinetics, Darmstadt, 64293, Germany.
  • Golob M; Nuvisan GmbH, Bioanalysis, Neu-Ulm, 89231, Germany.
  • Goodman J; Integrated Bioanalysis, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, CB21 6GH, UK.
  • Laurén A; Novo Nordisk A/S, Non-clinical & Clinical Assay Sciences, Global Discovery & Development Sciences, Global Drug Discovery, Maløv, DK-2760, Denmark.
  • Andersen L; Lundbeck A/S, Experimental Medicine & Clinical Development, Valby, DK-2500, Denmark representing Orphazyme A/S, Clinical Development, Copenhagen N, DK-2200, Denmark.
  • Decker P; Argenx BV, Bioanalytics, Zwijnaarde, 9052, Belgium.
  • Dejager L; UCB Pharma, Development Science, Translational Biomarkers & Bioanalysis, Chemin du Foriest, Braine-l'Alleud, B-1420, Belgium.
  • Fjording MS; BioAgilytix Labs, Lademannbogen 10, Hamburg, 22339, Germany.
  • Groenen P; Idorsia Pharmaceuticals Ltd., Translational Biomarkers, Allschwil, 4123, Switzerland.
  • Jasnowski R; Active Biomarkers, 60F Avenue Rockefeller, Lyon, 69008, France.
  • Justies N; Roche Innovation Center Basel, Roche Pharmaceutical Research & Early Development, Basel, 4070, Switzerland.
  • Kimberg M; Synexa Life Sciences BV, Leiden, 2333 CS, The Netherlands.
  • Kunz U; Boehringer Ingelheim Pharma GmbH & Co. KG, Translational Medicine & Clinical Pharmacology, Biberach an der Riss, 88397, Germany.
  • Lawrence J; F-star Therapeutics, Cambridge, CB22 3AT, UK.
  • Richter M; AbbVie Deutschland GmbH & Co KG, DMPK-BA, Knollstrasse, Ludwigshafen, 67061, Germany.
  • Sordé L; Sobi AG, Bioanalytical Sciences, Plan-les-Ouates, 1228, Switzerland.
  • Trigt RV; ICON Bioanalytical Laboratories, Assen, 9407 TK, The Netherlands.
  • Vermet L; Sanofi Research & Development, Translational Medicine & Early Development, Biomarkers & Clinical Bioanalysis, Montpellier, 34080, France.
  • Vitaliti A; Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, 4056, Switzerland.
  • Wright M; GlaxoSmithKline, Bioanalysis Immunogenicity & Biomarkers, Stevenage, SG1 2NY, UK.
  • Timmerman P; European Bioanalysis Forum, Brussels, 1000, Belgium.
Bioanalysis ; 14(13): 911-917, 2022 Jul.
Article en En | MEDLINE | ID: mdl-35904153
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Bioensayo Tipo de estudio: Prognostic_studies Idioma: En Revista: Bioanalysis Año: 2022 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Bioensayo Tipo de estudio: Prognostic_studies Idioma: En Revista: Bioanalysis Año: 2022 Tipo del documento: Article País de afiliación: Alemania